Xenikos aims to develop a new medicine, based on the action of toxin-conjugated antibodies that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos strives to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.
Latest news
16 november 2018
Introducing T-Guard®
T-Guard® is a medicine currently under development that safely and swiftly ‘resets’ the body’s immune system. It shows potential in the effective treatment of certain life-threatening immune conditions, such as transplant-related rejection, acute Graft versus Host Disease (aGVHD), solid-organ rejection and several severe autoimmune diseases.
Our investors
